Last updated: August 1, 2026
Vepesid is a brand of etoposide, a topoisomerase II inhibitor used mainly in combination chemotherapy for small-cell lung cancer, testicular cancer, lymphomas, leukemias and selected pediatric malignancies. Its core composition-of-matter patent protection has expired, generic etoposide is widely available, and the commercial market is mature. Current clinical development focuses on new combinations, delivery systems, treatment sequencing and biomarker-selected use rather than on Vepesid as a branded product.
What is Vepesid and how does etoposide work?
Vepesid contains etoposide, a semisynthetic podophyllotoxin derivative. Etoposide stabilizes the topoisomerase II-DNA complex, causing DNA strand breaks and cell-cycle arrest, particularly during the S and G2 phases.
Vepesid has been marketed in oral capsule and intravenous formulations. In the U.S., etoposide injection is also marketed under other names, including Toposar and generic labels. The FDA-approved indications for etoposide injection include:
- Small-cell lung cancer
- Refractory testicular tumors, in combination regimens
- Other malignancies under established oncology protocols, depending on formulation and jurisdiction
The prescribing label includes warnings for myelosuppression, secondary acute leukemia, hypersensitivity reactions and mucositis. Oral and intravenous dosing are not interchangeable because bioavailability and exposure differ by formulation (U.S. Food and Drug Administration [FDA], 2023).
What is the active ingredient in Vepesid?
The active ingredient is etoposide, also known as VP-16. Etoposide phosphate is a water-soluble prodrug used in some injectable products. Etoposide and etoposide phosphate are pharmacologically related but are not identical chemical entities.
What clinical trials are evaluating etoposide?
Etoposide remains active in clinical research, but most studies identify the drug by its generic name rather than by the Vepesid brand. The largest trial activity is in combination therapy.
Major clinical research areas
| Research area |
Role of etoposide |
Development status |
| Small-cell lung cancer |
Component of platinum-etoposide regimens, sometimes combined with immunotherapy |
Established standard in extensive-stage disease |
| Small-cell lung cancer maintenance |
Investigated with immune checkpoint inhibitors and newer targeted approaches |
Combination and sequencing research |
| Testicular cancer |
Component of BEP, EP and related regimens |
Established standard |
| Acute myeloid leukemia |
Included in salvage, induction or investigational combinations |
Active but protocol-dependent |
| Lymphoma |
Used in salvage chemotherapy, including ESHAP- and related regimens |
Established specialist use |
| Pediatric oncology |
Used in sarcoma, neuroblastoma, leukemia and other protocols |
Active cooperative-group research |
| Conditioning before stem-cell transplant |
Used in selected transplant regimens |
Established but variable by disease |
| Novel delivery systems |
Investigated through liposomal, nanoparticle and localized delivery concepts |
Earlier-stage research |
The National Cancer Institute and ClinicalTrials.gov list numerous studies containing etoposide. These trials generally evaluate a disease regimen, not a Vepesid-branded product. The commercial value of a positive result therefore accrues primarily to the newer combination, companion technology or delivery platform rather than to the legacy brand (National Cancer Institute, 2024; ClinicalTrials.gov, 2024).
Are there late-stage trials for Vepesid itself?
There is no major late-stage development program for Vepesid as a standalone branded product. Etoposide is already an established cytotoxic agent with decades of clinical use. New trials generally ask whether etoposide should be combined with:
- Platinum chemotherapy
- PD-1 or PD-L1 inhibitors
- Antibody-drug conjugates
- Targeted agents
- Hematopoietic stem-cell transplantation
- Radiotherapy
- Novel formulations designed to improve exposure or reduce toxicity
What is the FDA regulatory status of Vepesid?
Vepesid is an established oncology medicine rather than a new molecular entity. FDA regulatory activity is centered on approved generic etoposide products, labeling updates and manufacturing compliance.
FDA approval and dosage forms
| Product category |
Active ingredient |
Main route |
Regulatory position |
| Vepesid capsules |
Etoposide |
Oral |
Legacy branded formulation; availability varies |
| Etoposide injection |
Etoposide |
Intravenous |
Multiple approved generic products |
| Etoposide phosphate injection |
Etoposide phosphate |
Intravenous |
Alternative injectable form in certain markets |
The FDA label recognizes etoposide’s use in combination chemotherapy and includes dose modifications for renal impairment, hepatic dysfunction, marrow suppression and severe toxicity. The label also identifies a dose-related risk of secondary acute myeloid leukemia and a risk of anaphylactoid reactions during infusion (FDA, 2023).
What is the Orange Book status of Vepesid?
Vepesid has no meaningful remaining U.S. market exclusivity based on an unexpired composition-of-matter patent. Generic etoposide products have been available for many years.
The FDA Orange Book is most relevant to currently marketed reference-listed drugs and their approved generic equivalents. Older Vepesid listings may be inactive, discontinued or superseded by generic reference products depending on the dosage form and product history. The practical market position is clear: generic etoposide is available, and a new applicant would not face a conventional branded exclusivity barrier comparable to a recently approved oncology drug (FDA, 2024a).
How many patents cover Vepesid?
No commercially important, unexpired U.S. composition-of-matter patent protects etoposide. Historic patent families covered the molecule, synthesis and formulation, but those rights expired after the relevant statutory terms.
Potential residual rights could exist around:
- A specific injectable formulation
- Stabilizers or excipients
- A delivery device
- A liposomal or nanoparticle formulation
- A combination regimen
- A manufacturing process
- A new therapeutic use
Those rights would not recreate broad exclusivity for conventional oral or intravenous etoposide.
When does Vepesid lose exclusivity?
Vepesid’s core exclusivity expired years ago. The applicable U.S. patent term for a legacy product is no longer a material barrier to generic entry. Generic competition has already occurred in both oral and injectable etoposide markets.
The remaining commercial protections are operational rather than patent-based:
- Manufacturing scale
- Hospital formulary access
- Supplier reliability
- Sterile injectable compliance
- Procurement contracts
- Drug-shortage management
- Physician familiarity with established regimens
For this reason, Vepesid has limited ability to support premium pricing without a differentiated formulation or a new clinical indication.
What patent litigation affects Vepesid?
No major current U.S. patent litigation is associated with conventional Vepesid or generic etoposide. The principal litigation risk would arise from a newer product that incorporates etoposide into a protected delivery system or combination regimen.
Generic litigation and Paragraph IV risk
A conventional abbreviated new drug application for etoposide would generally face a low Paragraph IV risk because the core patents are expired or absent from the relevant listing. Litigation risk would be higher if the applicant targeted:
- A still-listed formulation patent
- A controlled-release oral product
- A branded injectable presentation
- A patented combination indication
- A protected manufacturing process
A Paragraph IV certification would challenge a listed patent as invalid, unenforceable or not infringed. For legacy etoposide, the likely barrier is regulatory documentation and product quality rather than patent litigation.
What formulations are protected by etoposide patents?
Historic formulation and process claims may cover specific combinations of etoposide with solvents, buffers, stabilizers or excipients. Injectable etoposide is technically more difficult to manufacture than a simple solid oral dosage form because of:
- Poor aqueous solubility
- Solvent-related toxicity
- Precipitation risk
- Container compatibility
- Sterility requirements
- Sensitivity to temperature and handling
Etoposide phosphate addresses some solubility limitations through a prodrug approach. Newer delivery systems could obtain patent protection if they show a meaningful improvement in stability, tolerability, pharmacokinetics or tumor exposure.
How strong is the Vepesid patent estate?
The patent estate is weak for the legacy product and potentially stronger for differentiated delivery technologies.
| Patent category |
Position for conventional Vepesid |
| Composition of matter |
Expired |
| Basic method of treatment |
Expired or limited by prior art |
| Oral etoposide formulation |
Generic competition established |
| Intravenous etoposide |
Generic competition established |
| Etoposide phosphate |
Product-specific rights largely mature |
| Novel delivery systems |
Potentially patentable |
| New combinations |
Depends on claim scope and clinical data |
| Manufacturing process |
Possible narrow protection |
| Pediatric or biomarker-selected use |
Potentially protectable, but difficult to enforce broadly |
The strongest future intellectual-property opportunity is not the Vepesid molecule itself. It is a reformulated or combination product with clinically demonstrated advantages.
What is the market outlook for Vepesid and generic etoposide?
The etoposide market is mature, price-sensitive and hospital-oriented. Revenue is distributed among multiple generic manufacturers and suppliers. Brand-level Vepesid revenue is likely a small portion of total etoposide sales where generic substitution is permitted.
Market drivers
Demand is supported by:
- Continued incidence of small-cell lung cancer
- Use in testicular cancer regimens
- Pediatric oncology protocols
- Hematologic malignancy treatment
- Stem-cell transplantation
- Low-cost inclusion in combination regimens
- Periodic shortages that increase supplier value
Market constraints
Growth is limited by:
- Generic price erosion
- Established clinical alternatives
- Toxicity and marrow suppression
- Substitution by newer immunotherapy combinations
- Hospital purchasing pressure
- Low differentiation among suppliers
- Limited branded prescribing
Five-year market projection
The following scenario represents a directional projection for the global etoposide market, including generic oral and injectable products. It excludes the broader sales of combination regimens such as platinum-immunotherapy products.
| Scenario |
Estimated annual market trend through 2029 |
Main assumptions |
| Low case |
Flat to down 2% annually |
Price erosion, reduced use in selected regimens |
| Base case |
1% to 3% annual growth |
Stable treatment volumes, modest cancer incidence growth |
| High case |
3% to 5% annual growth |
Increased oncology volume, supply constraints and new delivery products |
The base case implies a stable-volume, low-value market rather than a high-growth specialty pharmaceutical opportunity. Growth in patient treatment volume is likely to be offset partly by lower unit prices.
How does Vepesid compare with competing drugs?
Etoposide versus irinotecan
Etoposide is a topoisomerase II inhibitor, while irinotecan inhibits topoisomerase I. Irinotecan is used extensively in colorectal and small-cell lung cancer settings. Etoposide remains more entrenched in platinum-based small-cell lung cancer and testicular cancer regimens.
Etoposide versus topotecan
Topotecan is another topoisomerase I inhibitor used in relapsed small-cell lung cancer and other malignancies. Etoposide has broader historical use in front-line combination regimens, while topotecan is more associated with relapsed disease.
Etoposide versus newer small-cell lung cancer regimens
Atezolizumab, durvalumab and other immune checkpoint inhibitors have changed front-line extensive-stage small-cell lung cancer treatment, but they are generally used with platinum-etoposide rather than as direct replacements. Etoposide therefore remains embedded in major treatment pathways even as the value of the overall regimen shifts toward higher-priced immunotherapies.
What generic entry risks exist for Vepesid?
Generic entry is no longer a future event for Vepesid. It is the established market structure.
For a new generic manufacturer, the principal risks are:
- Sterile manufacturing failures.
- Injectable supply interruptions.
- Low reimbursement and limited margins.
- Difficulty obtaining hospital contracts.
- Competition from established suppliers.
- Raw-material and solvent availability.
- Formulation differences that affect bioequivalence or stability.
For the brand owner, the main risk is continued substitution and loss of formulary presence, not a new patent challenge.
What companies are active in the etoposide market?
The market includes the former brand owner, generic injectable manufacturers and regional oncology suppliers. Product availability varies by country and by dosage form. Major generic pharmaceutical companies have historically marketed etoposide products, while hospital distributors and contract manufacturers influence supply continuity.
Company-level market share changes frequently because of product discontinuations, manufacturing inspections, shortages and tender awards. The relevant competitive advantage is usually supply reliability rather than clinical differentiation.
What licensing deals affect Vepesid?
No major current licensing transaction is required to commercialize conventional etoposide in the United States because the molecule is off patent. Licensing value may arise in:
- Liposomal etoposide
- Long-acting injectable formulations
- Nanoparticle delivery
- Tumor-targeted conjugates
- Combination products
- Region-specific rights
- Manufacturing technology
A licensing transaction involving etoposide would therefore be evaluated as a platform or formulation deal, not as a transaction for rights to the legacy Vepesid molecule.
Key Takeaways
- Vepesid is a legacy brand of etoposide.
- Etoposide remains clinically important in small-cell lung cancer, testicular cancer, lymphoma, leukemia and pediatric oncology.
- Current trials evaluate etoposide in combinations, sequencing strategies and novel delivery systems.
- Core composition-of-matter exclusivity has expired.
- Generic etoposide is widely available, making Paragraph IV and brand litigation risk low for conventional products.
- The market is mature, price-sensitive and driven by hospital procurement.
- A reasonable five-year market outlook is flat to modest growth, with an estimated base-case annual increase of 1% to 3%.
- Future patent value would come from improved formulations, delivery systems, manufacturing methods or combination regimens.
Frequently Asked Questions
Is Vepesid still available?
Vepesid availability varies by country and dosage form. Generic etoposide injection is widely used, while the original branded product may have limited or discontinued distribution in some markets.
Is etoposide chemotherapy still used in 2024?
Yes. Etoposide remains a standard component of several oncology regimens, including platinum-etoposide treatment for small-cell lung cancer and etoposide-containing treatment for testicular cancer.
Does Vepesid have biosimilar competition?
No. Vepesid is a small-molecule chemotherapy drug, not a biologic. The relevant competitors are generic etoposide products, not biosimilars.
Can a new company patent etoposide?
A company generally cannot obtain a broad new patent on the old etoposide molecule. It may obtain narrower protection for a novel formulation, delivery system, manufacturing process, combination or treatment method that meets patentability requirements.
Is Vepesid a high-growth pharmaceutical market?
No. Conventional Vepesid and generic etoposide operate in a mature market. Higher growth would require a differentiated formulation, a new delivery platform or clinical data supporting a commercially valuable treatment strategy.
References
-
ClinicalTrials.gov. (2024). Search results for etoposide clinical studies. U.S. National Library of Medicine. https://clinicaltrials.gov/
-
National Cancer Institute. (2024). Etoposide. National Cancer Institute Drug Dictionary. https://www.cancer.gov/publications/dictionaries/cancer-drug/def/etoposide
-
U.S. Food and Drug Administration. (2023). Etoposide injection prescribing information. FDA Drugs@FDA. https://www.accessdata.fda.gov/scripts/cder/daf/
-
U.S. Food and Drug Administration. (2024a). Approved drug products with therapeutic equivalence evaluations. FDA Orange Book. https://www.fda.gov/drugs/drug-approvals-and-databases/orange-book-data-files
-
World Health Organization. (2023). WHO model list of essential medicines, 23rd list. World Health Organization. https://www.who.int/publications/i/item/WHO-MHP-HPS-EML-2023.02
